220 related articles for article (PubMed ID: 26709902)
61. Poly (ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice.
Sriram CS; Jangra A; Gurjar SS; Hussain MI; Borah P; Lahkar M; Mohan P; Bezbaruah BK
Pharmacol Biochem Behav; 2015 Jun; 133():83-91. PubMed ID: 25863272
[TBL] [Abstract][Full Text] [Related]
62. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
63. Modulation of DNA fragmentation factor 40 nuclease activity by poly(ADP-ribose) polymerase-1.
West JD; Ji C; Marnett LJ
J Biol Chem; 2005 Apr; 280(15):15141-7. PubMed ID: 15703174
[TBL] [Abstract][Full Text] [Related]
64. A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma.
Satchell MA; Zhang X; Kochanek PM; Dixon CE; Jenkins LW; Melick J; Szabó C; Clark RS
J Neurochem; 2003 May; 85(3):697-708. PubMed ID: 12694396
[TBL] [Abstract][Full Text] [Related]
65. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
66. PARP inhibitors: new tools to protect from inflammation.
Giansanti V; Donà F; Tillhon M; Scovassi AI
Biochem Pharmacol; 2010 Dec; 80(12):1869-77. PubMed ID: 20417190
[TBL] [Abstract][Full Text] [Related]
67. Poly (ADP-ribose) polymerase inhibition protects against myocardial ischaemia/reperfusion injury via suppressing mitophagy.
Cao S; Sun Y; Wang W; Wang B; Zhang Q; Pan C; Yuan Q; Xu F; Wei S; Chen Y
J Cell Mol Med; 2019 Oct; 23(10):6897-6906. PubMed ID: 31379115
[TBL] [Abstract][Full Text] [Related]
68. Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.
Besson VC
Br J Pharmacol; 2009 Jul; 157(5):695-704. PubMed ID: 19371326
[TBL] [Abstract][Full Text] [Related]
69. Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia.
Nagayama T; Simon RP; Chen D; Henshall DC; Pei W; Stetler RA; Chen J
J Neurochem; 2000 Apr; 74(4):1636-45. PubMed ID: 10737622
[TBL] [Abstract][Full Text] [Related]
70. Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3.
Sherstyuk YV; Ivanisenko NV; Zakharenko AL; Sukhanova MV; Peshkov RY; Eltsov IV; Kutuzov MM; Kurgina TA; Belousova EA; Ivanisenko VA; Lavrik OI; Silnikov VN; Abramova TV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892271
[TBL] [Abstract][Full Text] [Related]
71. Poly(ADP-ribose)polymerase inhibition - where now?
Woon EC; Threadgill MD
Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
[TBL] [Abstract][Full Text] [Related]
72. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
73. Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1.
Zaniolo K; Desnoyers S; Leclerc S; Guérin SL
BMC Mol Biol; 2007 Oct; 8():96. PubMed ID: 17961220
[TBL] [Abstract][Full Text] [Related]
74. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
[TBL] [Abstract][Full Text] [Related]
75. Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure.
Slominska EM; Kowalik K; Smolenski RT; Szolkiewicz M; Rutkowski P; Rutkowski B; Swierczynski J
Pediatr Nephrol; 2006 Jun; 21(6):800-6. PubMed ID: 16604373
[TBL] [Abstract][Full Text] [Related]
76. Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1.
Yeh TY; Sbodio JI; Nguyen MT; Meyer TN; Lee RM; Chi NW
Mol Cell Biochem; 2005 Aug; 276(1-2):183-92. PubMed ID: 16132700
[TBL] [Abstract][Full Text] [Related]
77. Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes.
Zhang J; Chatterjee K; Alano CC; Kalinowski MA; Honbo N; Karliner JS
J Cardiovasc Pharmacol; 2010 Mar; 55(3):219-26. PubMed ID: 20375713
[TBL] [Abstract][Full Text] [Related]
78. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
Morales J; Li L; Fattah FJ; Dong Y; Bey EA; Patel M; Gao J; Boothman DA
Crit Rev Eukaryot Gene Expr; 2014; 24(1):15-28. PubMed ID: 24579667
[TBL] [Abstract][Full Text] [Related]
79. Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide.
Cosi C; Marien M
Ann N Y Acad Sci; 1999; 890():227-39. PubMed ID: 10668429
[TBL] [Abstract][Full Text] [Related]
80. Mediation of cell death by poly(ADP-ribose) polymerase-1.
Koh DW; Dawson TM; Dawson VL
Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
